Member Info for 1DayRodney

Snap

Our distributor fir the AIHL assay hss just issyed a launch RNS

https://www.lse.co.uk/rns/IHC/launch-of-test-to-avoid-hearing-loss-in-neonates-zjef3zr5yz4xok7.html

NICE promoting their AIHL review on Twitter..

https://twitter.com/NICEComms/status/1508807461918105606?t=V2tB-kI0JdUD6gVc6Cq-6A&s=19

Listening to the presentation on AIHL, David mentioned that Inspiration Healthcare were in a 'soft launch' period. I don't think he knew they've actually launched 'fully' on their website with it's own dedicated section... this may take off quicker than he realizes!

I think basically everyone's waiting for confirmed sales to prove CEO's bold statement of
"We believe the Company is well positioned to deliver on shareholder value".

Because he hasn't for the last two years. Only continual dilution, bad marketing and unjustifiable salary levels.
Nothing in the company's recent history has shown positive income from any product despite the various statements of 'sales this xxxx', 'ready for market by xxxx' etc.

Until this happens, this will remain a trader's rather than investor's share and will be avoided by any new institutional investor.

This may help.....

https://www.shiftingshares.com/what-is-a-price-monitoring-extension/

PALOH Study conclusion:

"This study demonstrates that genotyping can be performed in the acute setting and incorporated into clinical practice without disrupting existing standards of care. Based on the population frequency of the m.1555A>G variant, and the worldwide use of aminoglycosides in more than 7 million neonates each year, the adoption of a MT-RNR1 POCT would potentially avoid thousands of AIO cases annually, particularly in low- and middle-income countries where aminoglycosides are widely prescribed.28 There are a growing number of acute clinical scenarios where knowledge of an individual’s genotype could be used to improve outcomes, and the SARS-CoV-2 pandemic has led to the proliferation of in vitro diagnostic systems that could be redeployed for rapid genotyping.29 This trial demonstrates a technological approach to perform genotyping that allows genotype to be integrated into acute clinical pathways without disrupting normal standards of care"

This opens us up for manner of future assays and company growth :))

Sledgey wrote
"Fortunately Delta-con has milder symptoms."

If you are comparing it to all other Covid19 variants, then as we speak, this statement is misleading, unfounded and speculative.

There is not enough scientific data for 'deltacron' to determine if it any milder or severe than previuos dominant variants at this time.
You also have to take into account the diminishing response of previously administered inoculations amongst the populous.

Would be nice to get it into the NHS even if it were just at community/GP surgery level.

I think another uk market we should be looking at is high street pharmacies who may already be offering a Covid service but maybe via 3rd party such as Boots or get it into nationwide local multi-branch community pharmacies like Lloyds, Well etc. Many GP surgeries have an associated or attached pharmacy.

It would also be great to get a wedge of professional sports clubs market too. Dump useless LFT and reclaim the time wasted waiting for PCR.

I know we now have a couple of localised distributors in the EU, but do you have to be on the EU HSC common list to sell the POC COV generally in the EU (similar to our CTDA?)? It appears we are not yet on the list...

https://covid-19-diagnostics.jrc.ec.europa.eu/devices/detail/2524

I'd like to think that the soon (fingers crossed) CTDA approval is going to give this a kick up the 'arris. I presuming GDR will selling direct as no UK distributor has yet been mentioned.

I would also like to see an update on the MNR1 trials being carried out in Greece.
It's been well over a year since the UK PALOH trial was completed and the the leader of the trial has presented the results several times at various conferences. It's disappointing as to why is it taking so long to publish (NICE?) and get this life changing device to market/NHS. GDR website shows IHC as UK distributor but it's not yet shown on IHC website.
RNS 3rd March last year said launch was "on track for Summer 2021" :S

I don't know what magic Mr Budd whispers into the ears of the voting shareholders to keep his position, but GDR has lit a lot of fuses in the past 2yrs and it's about time one of them finally reached a firework!!!

GLA

Hagtagshares wrote:

"Covid has disappeared from the agenda"

It may not be topical but it certainly hasn't gone away. I dropped off a delivery to a care home yesterday and they're been struck down with it at the moment. It isn't going anywhere fast and could take a nasty twist. UK Government are still pursuing additional boosters this spring and autumn for certain sectors of society, so despite Boris' bravado, he's still hedging his bets and it's still on their agenda.

Not saying any of this is going affect or help GDR with the sale of the Covid POC. That is still in their own hands....

Lloyd88 wrote:

"UK can effectively be written off now unless there's a new and nasty variant forcing the UK Govt to back track and suddenly look at products such as those made by GDR."

I don't totally agree with this.
I think any UK market for the Covid POC will be the likes of Boots, Lloyds Pharmacy etc. where accurate, rapid, reasonably priced but still profitable (to the the seller) tests can be carried out. Maybe even GP's/ health centres - a good potential market. But I agree, not for any 'mass' testing scenario where the govt directly places orders.

Overall I think this is positive news.

I think the statement about the UK market is an unfortunate situation all companies face in the sector due to the government's dreadful, lacklustre, unsupportive and muddled attitude to the professional UK diagnostic industry during this Covid pandemic. Raising the 'standards' gate now at their convenience even though they were being told all along that a lot of the tests they were using (and still are 'til the end if the month) were pants!!

But it's good to see pro-active evaluation in the UK market is taking place now prior to the expected CTDA approval.

We already have an agreement with a distributor for the AIHL product which was notified in an RNS 24th April 2020 (nearly 2yrs ago!).

"Inspiration Healthcare to distribute genedrive's Antibiotic Induced Hearing Loss test in UK & Ireland.
Option to expand agreement to engage Inspiration Healthcare's global neonatal sub-distributor network"

Let's hope GDR get their skates on and finally put partnership into action!!!

I guessing from the term 'Biological Warfare target' and the US mains lead shown, that this is the unit and assays we are hopefully supplying to our DOD friends across the pond via Mountain Horse Solutions.

Interesting potential market - mobile high quality door to door testing?

https://www.dailymail.co.uk/news/article-10467937/Care-bosses-call-rapid-PCR-style-Covid-tests-brought-homes.html

@Lloyd
This presentation is not out of the ordinary, we had one same time last year, similarly for the November ones.
This presentation will be more interesting for it's future outlook on sales of existing products and any new products.

However, I'm pleased to see that a simple RNS notifying of a presentation has a surprisingly upbeat response from you, compared to your usual posts.

I'm sure the sales figures for the period quoted will be extremely light but I'm equally sure your predictive skills and inside knowledge of what is going to happen between now and the presentation will allow you to make a killing in trading this.
Good luck...

It seems GDR are scheduled for the publication of the advisory or so called 'medtech innovations' briefing held by NICE for one of our POC devices.

https://www.nice.org.uk/about/what-we-do/our-programmes/nice-advice/medtech-innovation-briefings

https://www.nice.org.uk/guidance/indevelopment?sp=on&nat=Medtech%20innovation%20briefings

Publication date is expected to be the 1st March.
My thoughts are this is likely for our AIHL POC. Hopefully one of the final hurdles to getting it into hospitals if it is :)

That sounds like a good question for the AGM on 30th Dec.

FYI
If anyone is interested, according to the AGM notice pdf on the Genedrive website, 'shareholders are encouraged to submit questions'. Questions can be submitted for the AGM by email to:
info@genedrive.com
with "AGM Question" in the subject line.

*make out to be